Taken together, results presented here suggest that MLH1/PMS2 downregulation could constitute a first-in-class predictive marker for response to HER2 inhibition in endocrine-therapy-resistant ER+/HER2− breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.